The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

AstraZeneca PLC

NYSE: AZN
Last

(U.S.) $29.35

Today's change-0.16 -0.54%
Updated February 24 4:03 PM EST. Delayed by at least 15 minutes.
 

AstraZeneca PLC

NYSE: AZN
Last

(U.S.) $29.35

Today's change-0.16 -0.54%
Updated February 24 4:03 PM EST. Delayed by at least 15 minutes.

AstraZeneca PLC down (U.S.)$0.16

AstraZeneca PLC closed lower Friday, dropping (U.S.)$0.16 or 0.54% to (U.S.)$29.35. Over the last five days, shares have gained 0.65% and 7.43% year to date. Shares have underperformed the S&P 500 by 21.99% during the last year.

Key company metrics

  • Open(U.S.) $29.23
  • Previous close(U.S.) $29.51
  • High(U.S.) $29.36
  • Low(U.S.) $29.20
  • Bid / Ask-- / --
  • YTD % change+7.43%
  • Volume3,539,599
  • Average volume (10-day)5,265,999
  • Average volume (1-month)6,772,644
  • Average volume (3-month)7,304,804
  • 52-week range(U.S.) $25.55 to (U.S.) $35.04
  • Beta0.83
  • Trailing P/E21.24×
  • P/E 1 year forward16.07×
  • Forward PEG2.09×
  • Indicated annual dividend(U.S.) $1.40
  • Dividend yield4.77%
  • Trailing EPS(U.S.) $1.38
Updated February 24 4:03 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+14.81%

Based on its net profit margin of 14.81%, AstraZeneca PLC is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX1.57%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue5,5855,6995,6036,115
Total other revenue--------
Total revenue5,5855,6995,6036,115
Gross profit4,4684,8584,5605,120
Total cost of revenue1,1178411,043995
Total operating expense3,0524,6715,3005,077
Selling / general / administrative2,1331,9682,1912,203
Research & development1,4811,3371,3841,429
Depreciation / amortization298297309263
Interest expense (income), net operating--------
Unusual expense (income)-835335765263
Other operating expenses, total-1,142-107-392-76
Operating income2,5331,0283031,038
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax2,183676-30723
Income after tax1,817995-31625
Income tax, total366-319198
Net income1,8421,014-3646
Total adjustments to net income--------
Net income before extra. items1,8421,014-3646
Minority interest25192821
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,8421,014-3646
Inc. avail. to common incl. extra. items1,8421,014-3646
Diluted net income1,8421,014-3646
Dilution adjustment00--0
Diluted weighted average shares1,2661,2661,2651,265
Diluted EPS excluding extraordinary itemsvalue per share1.450.800.000.51
Dividends per sharevalue per share1.850.000.910.00
Diluted normalized EPSvalue per share0.941.070.590.73